Hala Research Center of IRI, FDA, Tehran, Iran.
School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Cardiovasc Drugs Ther. 2022 Feb;36(1):131-155. doi: 10.1007/s10557-020-07052-3. Epub 2020 Sep 14.
Cardiovascular diseases (CVDs) are the leading global cause of mortality and disability, tending to happen in younger individuals in developed countries. Despite improvements in medical treatments, the therapy and long-term prognosis of CVDs such as myocardial ischemia-reperfusion, atherosclerosis, heart failure, cardiac hypertrophy and remodeling, cardiomyopathy, coronary artery disease, myocardial infarction, and other CVDs threatening human life are not satisfactory enough. Therefore, many researchers are attempting to identify novel potential therapeutic methods for the treatment of CVDs. Melatonin is an anti-inflammatory and antioxidant agent with a wide range of therapeutic properties. Recently, several investigations have been carried out to evaluate its effectiveness and efficiency in CVDs therapy, focusing on mechanistic pathways. Herein, this review aims to summarize current findings of melatonin treatment for CVDs.
心血管疾病 (CVDs) 是全球主要的死亡和致残原因，在发达国家往往发生在年轻人中。尽管医疗治疗有所改善，但心肌缺血再灌注、动脉粥样硬化、心力衰竭、心脏肥大和重构、心肌病、冠心病、心肌梗死等 CVD 的治疗和长期预后仍不尽如人意，其他威胁人类生命的 CVD 也是如此。因此，许多研究人员正在试图寻找治疗 CVD 的新的潜在治疗方法。褪黑素是一种具有广泛治疗特性的抗炎和抗氧化剂。最近，已经进行了几项研究来评估其在 CVD 治疗中的有效性和效率，重点是机制途径。本文旨在总结褪黑素治疗 CVD 的现有研究结果。
